Advanced CancerSHAPENCT03325218
Survival Expectations and Hope Among Cancer Patients at End-of-Life
An observational study of Advanced Cancer, run by Duke-NUS Graduate Medical School at 2 sites in Singapore.
Trial summary
Literature shows that less than half of advanced cancer patients accurately understand their prognosis, with most being overly optimistic. Investigators suspect that many patients are reporting not what they believe, but what they would like to believe. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Advanced Cancer
- How many people
- 214 participants
- Where
- 2 sitesSingapore
- Study dates
- 1 Apr 2018to 31 Mar 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This is a cross-sectional study of 200 patients with Stage IV cancer with expected survival of less than one year. Eligible patients will be recruited from National Cancer Centre (NCC) and Singapore General Hospital (SGH). Following an informed consent, patients will be randomized to receive one of the two sets of the survey questionnaire, which differ in how the prognostic questions are asked
Who may be able to join
- The inclusion criteria for patients are:
- Age ≥ 21 years old
- Singaporean/Singapore Permanent Resident (PR)
- Diagnosed with advanced cancer by the primary physician
- Prognosis of ≤ 1 year as determined by the primary treating oncologist responding "YES" to the question "Do you believe that there is a high chance (greater than 50%) that this patient is unlikely to be alive in 12 months?" Only patients for whom the physicians respond as "YES" will be approached to participate in the study
Who cannot join
- Patients deemed to be mentally incompetent and those not aware of their diagnosis.
Trial locations and contacts
2 sites in 1 country.
Singapore2 sites
Singapore General Hospital
Singapore, Singapore, 169608
National Cancer Centre Singapore
Singapore, Singapore, 169610
About this study
Literature shows that less than half of advanced cancer patients accurately understand their prognosis, with most being overly optimistic. Investigators suspect that many patients are reporting not what they believe, but what they would like to believe. This study aims to discern patient's beliefs about prognosis independent of hope, to identify factors that influence patient's beliefs, and to explore patient preferences for prognostic information.
Investigators propose to randomize 200 cancer patients with a prognosis of less than one year to receive one of the two versions of a survey. Investigators hypothesize that, although many patients will continue to be overly optimistic about their prognosis, those patients responding to Version 2, followed by Version 1, will provide more accurate estimates.
Efforts to improve decision making require an understanding of patients' beliefs and preferences for receiving prognostic information and identifying strategies to clearly convey that information. This study will fill that gap.
Read the detailed description
Cancer burden is increasing in Singapore. As Singapore's population increases, so too does the incidence of cancer. A total of 61,519 incident cancer cases were diagnosed in Singapore between 2010-2014. High disease incidence has resulted in a greater fiscal burden for patients and the health system as cancer patients consume a disproportionate amount of healthcare resources.Despite improved treatments, cancer related mortality is high; cancer has overtaken diseases of the circulatory system (including ischemic heart disease) to become the leading cause of death in Singapore. It now accounts for nearly 30% of all deaths. Given these sobering statistics, policy makers are struggling with how best to cost-effectively accommodate the health care needs of this vulnerable population.
Many Patients Want to Know Their Prognosis. A recent systematic review showed that the majority of cancer patients (and their caregivers) expressed a desire for prognostic information and how it varies by treatment choice. However, the preferred style for receiving that information varied. One study showed that nearly 80% of patients wanted a qualitative prognosis (i.e. will they die from the disease) whereas only half wanted a quantitative prognosis (i.e. how long they will survive). Regardless of how the information is conveyed, studies have shown that patients who discuss prognosis with their physicians have a better understanding of the disease trajectory, are more likely to pursue comfort-oriented over life-prolonging care, and are better able to cope with their illness and clarify priorities and goals.
Physicians Often Withhold Prognostic Information. Despite many patient's preferences for prognostic information, the literature reveals a reluctance among physicians' to disclose information about prognosis when it is poor.8 Physicians often find it easier to offer aggressive treatments rather than engage in challenging end-of-life discussions.In Singapore, as with other Asian countries, physicians often collude with caregivers to hide prognostic information from patients. Even when discussed, patients may fail to understand and recall the information presented because of unfamiliar terminology, such as "median survival" or "relative/absolute risk reduction".In many cases, patients are reluctant to ask additional questions about prognoses even though they may desire this information.
Systematic bias in Prognosis. If lack of communication were the sole cause of poor prognostic information, then patient's beliefs about their prognosis would be associated with high variance, but not necessarily biased in a particular direction. Yet, most patients with advanced cancer state unrealistic expectations about the benefits of treatment, believe that their cancer is curable and over-estimate their predicted life expectancy.This bias results from several factors. First, patients who are managing their symptoms well, have strong social and family support, and/or are happy with other aspects of their care may suffer from a form of halo effect, which is a cognitive bias where their chances of a cure are positively influenced by these other properties.Second, patients diagnosed with cancer at early stages are often (rightly) presented with optimistic chances of survival. For those whose cancer progresses, even when informed with the new information, they are less likely to fully update their prior beliefs as compared to someone first diagnosed at a later stage. This lack of complete updating is consistent with confirmatory bias where people give disproportionately less consideration to new information that does not conform to their prior expectations.However, even those newly diagnosed at a later stage are likely to be overly optimistic about their chances for a cure.Although there are negative consequences from this form of optimism bias, such as overtreatment, it can also be part of a successful coping strategy.In fact, the benefits of 'forcing' patients to understand their prognosis may not be worth the costs due to the additional emotional distress it may inflict. This may hold true even if hope leads patients to undergo costly and burdensome treatments with a low probability of success. However, it is still important to understand the extent of divergence between hope and beliefs, the level and type of information that patients would like to receive and how best to convey that information.
Discerning Hope from Beliefs. To discern whether or not patients have an accurate understanding of their prognosis requires disentangling what they believe will occur from what they hope will occur. There are two promising strategies that allow for producing these estimates. The first strategy is to ask patients about their own beliefs, and then to compare their responses to how they believe their physician would respond. If their physician has provided them with accurate prognostic information, then eliciting the physicians' frame should allow for a more accurate assessment of beliefs less likely to be confounded by hope. Consistent with this hypothesis, a study of advanced cancer patients in the US reveals that the degree of prognostic discordance between physicians and patients decreases when patients are asked to respond using the physician's frame of reference.Yet, a second study using a similar approach still found very high discordance, which suggests either poor patient-physician communication or that using the physician's frame does not entirely reduce the confounding of hope and beliefs.
A second approach is to offer what economists term 'an incentive compatible strategy. Consistent with the idea that 'ignorance is bliss', even if patients are aware of their prognosis, many may prefer to express false hope rather than state the truth about their condition. In economic terms their utility (a measure of happiness) is higher when they express false hope. To encourage these individuals to state their true beliefs, they can be offered a reward such that the utility of expressing their true beliefs plus the reward is greater than the utility when they express false hope. Because the reward makes it in the best interest of the participant to reveal his/her beliefs truthfully, such incentive compatible approaches are sometimes known as truth serums.It is often operationalized by stating that the reward will be provided if the responses match the views of a professional (i.e., their physician) or the best evidence from the literature. For example, in one US study, college students were asked to rank the mortality risk from 12 different causes of death. Those offered a reward for correct rankings were more likely to rank the mortality risks accurately for their own age group.
- Conditions
- Advanced Cancer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Questionnaire Set A | Not described | |
| Questionnaire Set B | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The proportion of patients who knew they can not be cured
The primary aim of this study is to attempt to discern patient's beliefs about their prognosis independent of hope. We propose to address this aim by randomizing 200 Stage IV cancer patients with a prognosis of less than a year to receive one of the two sets of a carefully designed and pilot tested survey. Set A includes prognosis questions similar to those used in prior studies. Set B is identical to Set A but incorporates an incentive compatible strategy where a reward is offered for 'correct' answers, as determined by their treating physician's prediction. The incentive compatible approach has been shown to increase the accuracy of responses in a wide range of domains, including mortality risk predictions. We hypothesize that, although many patients will continue to convey an overly optimistic assessment of their prognosis, those patients responding to Set B followed by Set A, will provide more accurate estimates.
Measured: Baseline
Secondary outcomes (1)
The percentage of patients who received the information the way they would have liked
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2017
- Study start1 Apr 2018
- Primary completion31 May 2019
- Study completion31 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 214 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke-NUS Graduate Medical School
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Centre, Singapore, National University Hospital, Singapore
- Responsible party
- Principal investigator, Eric A. Finkelstein, Duke-NUS Graduate Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03325218
- Sponsor's protocol ID
- 2017/2181
- Acronym
- SHAPE
- Status last verified
- Feb 2025
- First submitted
- 4 Oct 2017
- Last updated
- 6 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Survival Expectations and Hope Among Cancer Patients at End-of-Life
- ClinicalTrials.gov ID
- NCT03325218
- Acronym / sponsor ID
- SHAPE / 2017/2181
- Conditions
- Advanced Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 214 participants (actual)
- Lead sponsor
- Duke-NUS Graduate Medical SchoolUniversity, hospital or other
- Collaborators
- National Cancer Centre, Singapore, National University Hospital, Singapore
- Study start
- 1 Apr 2018 (actual)
- Primary completion
- 31 May 2019 (actual)
- Study completion
- 31 Mar 2022 (actual)
- First posted
- 30 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Literature shows that less than half of advanced cancer patients accurately understand their prognosis, with most being overly optimistic. Investigators suspect that many patients are reporting not what they believe, but what they would like to believe. This study aims to discern patient's beliefs about prognosis independent of hope, to identify factors that influence patient's beliefs, and to explore patient preferences for prognostic information.
Investigators propose to randomize 200 cancer patients with a prognosis of less than one year to receive one of the two versions of a survey. Investigators hypothesize that, although many patients will continue to be overly optimistic about their prognosis, those patients responding to Version 2, followed by Version 1, will provide more accurate estimates.
Efforts to improve decision making require an understanding of patients' beliefs and preferences for receiving prognostic information and identifying strategies to clearly convey that information. This study will fill that gap.
Detailed description
Cancer burden is increasing in Singapore. As Singapore's population increases, so too does the incidence of cancer. A total of 61,519 incident cancer cases were diagnosed in Singapore between 2010-2014. High disease incidence has resulted in a greater fiscal burden for patients and the health system as cancer patients consume a disproportionate amount of healthcare resources.Despite improved treatments, cancer related mortality is high; cancer has overtaken diseases of the circulatory system (including ischemic heart disease) to become the leading cause of death in Singapore. It now accounts for nearly 30% of all deaths. Given these sobering statistics, policy makers are struggling with how best to cost-effectively accommodate the health care needs of this vulnerable population.
Many Patients Want to Know Their Prognosis. A recent systematic review showed that the majority of cancer patients (and their caregivers) expressed a desire for prognostic information and how it varies by treatment choice. However, the preferred style for receiving that information varied. One study showed that nearly 80% of patients wanted a qualitative prognosis (i.e. will they die from the disease) whereas only half wanted a quantitative prognosis (i.e. how long they will survive). Regardless of how the information is conveyed, studies have shown that patients who discuss prognosis with their physicians have a better understanding of the disease trajectory, are more likely to pursue comfort-oriented over life-prolonging care, and are better able to cope with their illness and clarify priorities and goals.
Physicians Often Withhold Prognostic Information. Despite many patient's preferences for prognostic information, the literature reveals a reluctance among physicians' to disclose information about prognosis when it is poor.8 Physicians often find it easier to offer aggressive treatments rather than engage in challenging end-of-life discussions.In Singapore, as with other Asian countries, physicians often collude with caregivers to hide prognostic information from patients. Even when discussed, patients may fail to understand and recall the information presented because of unfamiliar terminology, such as "median survival" or "relative/absolute risk reduction".In many cases, patients are reluctant to ask additional questions about prognoses even though they may desire this information.
Systematic bias in Prognosis. If lack of communication were the sole cause of poor prognostic information, then patient's beliefs about their prognosis would be associated with high variance, but not necessarily biased in a particular direction. Yet, most patients with advanced cancer state unrealistic expectations about the benefits of treatment, believe that their cancer is curable and over-estimate their predicted life expectancy.This bias results from several factors. First, patients who are managing their symptoms well, have strong social and family support, and/or are happy with other aspects of their care may suffer from a form of halo effect, which is a cognitive bias where their chances of a cure are positively influenced by these other properties.Second, patients diagnosed with cancer at early stages are often (rightly) presented with optimistic chances of survival. For those whose cancer progresses, even when informed with the new information, they are less likely to fully update their prior beliefs as compared to someone first diagnosed at a later stage. This lack of complete updating is consistent with confirmatory bias where people give disproportionately less consideration to new information that does not conform to their prior expectations.However, even those newly diagnosed at a later stage are likely to be overly optimistic about their chances for a cure.Although there are negative consequences from this form of optimism bias, such as overtreatment, it can also be part of a successful coping strategy.In fact, the benefits of 'forcing' patients to understand their prognosis may not be worth the costs due to the additional emotional distress it may inflict. This may hold true even if hope leads patients to undergo costly and burdensome treatments with a low probability of success. However, it is still important to understand the extent of divergence between hope and beliefs, the level and type of information that patients would like to receive and how best to convey that information.
Discerning Hope from Beliefs. To discern whether or not patients have an accurate understanding of their prognosis requires disentangling what they believe will occur from what they hope will occur. There are two promising strategies that allow for producing these estimates. The first strategy is to ask patients about their own beliefs, and then to compare their responses to how they believe their physician would respond. If their physician has provided them with accurate prognostic information, then eliciting the physicians' frame should allow for a more accurate assessment of beliefs less likely to be confounded by hope. Consistent with this hypothesis, a study of advanced cancer patients in the US reveals that the degree of prognostic discordance between physicians and patients decreases when patients are asked to respond using the physician's frame of reference.Yet, a second study using a similar approach still found very high discordance, which suggests either poor patient-physician communication or that using the physician's frame does not entirely reduce the confounding of hope and beliefs.
A second approach is to offer what economists term 'an incentive compatible strategy. Consistent with the idea that 'ignorance is bliss', even if patients are aware of their prognosis, many may prefer to express false hope rather than state the truth about their condition. In economic terms their utility (a measure of happiness) is higher when they express false hope. To encourage these individuals to state their true beliefs, they can be offered a reward such that the utility of expressing their true beliefs plus the reward is greater than the utility when they express false hope. Because the reward makes it in the best interest of the participant to reveal his/her beliefs truthfully, such incentive compatible approaches are sometimes known as truth serums.It is often operationalized by stating that the reward will be provided if the responses match the views of a professional (i.e., their physician) or the best evidence from the literature. For example, in one US study, college students were asked to rank the mortality risk from 12 different causes of death. Those offered a reward for correct rankings were more likely to rank the mortality risks accurately for their own age group.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Questionnaire Set A | – | – |
| Questionnaire Set B | – | – |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This is a cross-sectional study of 200 patients with Stage IV cancer with expected survival of less than one year. Eligible patients will be recruited from National Cancer Centre (NCC) and Singapore General Hospital (SGH). Following an informed consent, patients will be randomized to receive one of the two sets of the survey questionnaire, which differ in how the prognostic questions are asked
Key inclusion criteria (5 listed)
- The inclusion criteria for patients are:
Key exclusion criteria (1 listed)
- Patients deemed to be mentally incompetent and those not aware of their diagnosis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The proportion of patients who knew they can not be cured
Time frame: Baseline
The primary aim of this study is to attempt to discern patient's beliefs about their prognosis independent of hope. We propose to address this aim by randomizing 200 Stage IV cancer patients with a prognosis of less than a year to receive one of the two sets of a carefully designed and pilot tested survey. Set A includes prognosis questions similar to those used in prior studies. Set B is identical to Set A but incorporates an incentive compatible strategy where a reward is offered for 'correct' answers, as determined by their treating physician's prediction. The incentive compatible approach has been shown to increase the accuracy of responses in a wide range of domains, including mortality risk predictions. We hypothesize that, although many patients will continue to convey an overly optimistic assessment of their prognosis, those patients responding to Set B followed by Set A, will provide more accurate estimates.
1 secondary outcome
The percentage of patients who received the information the way they would have liked
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Advanced Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Advanced Cancer, run by Duke-NUS Graduate Medical School at 2 sites in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The proportion of patients who knew they can not be cured (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2025.